Shine Technologies is opening a facility in the U.S. that will focus on the production of lutetium-177 (Lu-177), a medical isotope used in targeted cancer therapies.
The new facility will operate at the company's headquarters in Janesville, WI. Shine said it is expected to have an initial production capacity of 100,000 doses of Lu-177 per year and will expand to a production capacity of 200,000 doses per year in the future.
The company expects equipment installation at the new facility to be complete in July and to have product available for commercial use by late 2023. Additionally, it has begun design and licensing processes for a dedicated therapeutic medical isotope production facility in Europe. Shine said it expects the European facility to have a similar production capacity to its U.S. facility.
